You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Cytomegalovirus as a Novel Target for Immunotherapy of Glioblastoma Multiforme
|
|---|---|
| Published in |
Frontiers in oncology, October 2014
|
| DOI | 10.3389/fonc.2014.00275 |
| Pubmed ID | |
| Authors |
Andrea Schuessler, David G. Walker, Rajiv Khanna |
| Abstract |
Progress in the treatment of glioblastoma multiforme (GBM) over the last few decades has remained marginal and GBM is still universally fatal with short survival times after initial diagnosis. Much research is focused on finding new therapeutics for GBM and immune-based approaches have shown great promise. The detection of cytomegalovirus (CMV) antigens in malignant cells has suggested that treatment strategies based on immunological intervention, such as adoptive transfer of antiviral T cells or vaccination with viral epitopes, could be exploited as cancer therapy. Here, we review the rationale for using CMV as a therapeutic target and discuss the first clinical evidence for safety and efficacy of CMV-specific cellular immunotherapy for GBM. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 65 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 2% |
| Czechia | 1 | 2% |
| Korea, Republic of | 1 | 2% |
| Unknown | 62 | 95% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 14 | 22% |
| Student > Bachelor | 14 | 22% |
| Student > Ph. D. Student | 13 | 20% |
| Other | 5 | 8% |
| Student > Master | 4 | 6% |
| Other | 7 | 11% |
| Unknown | 8 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 21 | 32% |
| Agricultural and Biological Sciences | 21 | 32% |
| Biochemistry, Genetics and Molecular Biology | 5 | 8% |
| Immunology and Microbiology | 2 | 3% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
| Other | 6 | 9% |
| Unknown | 8 | 12% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 January 2024.
All research outputs
#7,778,510
of 25,374,647 outputs
Outputs from Frontiers in oncology
#2,721
of 22,416 outputs
Outputs of similar age
#78,548
of 267,625 outputs
Outputs of similar age from Frontiers in oncology
#22
of 95 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 87% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 267,625 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 70% of its contemporaries.
We're also able to compare this research output to 95 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 76% of its contemporaries.